journal article·2023-07-25

Bioinspired pH-Responsive Microalgal Hydrogels for Oral Insulin Delivery with Both Hypoglycemic and Insulin Sensitizing Effects

Chaojie Ren, Danni Zhong, Yuchen Qi, Chaoyi Liu, Xingyu Liu, Shihong Chen, Sheng Yan, Min Zhou

ACS Nano· Volume 17· Issue 14
Publisher page

Abstract

The oral form of insulin is more convenient and has better patient compliance than subcutaneous or intravenous insulin. Current oral insulin preparations, however, cannot overcome the enzyme barrier, chemical barrier, and epithelial barrier of the gastrointestinal tract completely. In this study, a microalgae-based oral insulin delivery strategy (CV@INS@ALG) was developed using Chlorella vulgaris (CV)-based insulin delivery system cross-linking with sodium alginate (ALG). CV@INS@ALG could overcome the gastrointestinal barrier, protect insulin from harsh gastric conditions, and achieve a pH-responsive drug release in the intestine. CV@INS@ALG might contribute to two mechanisms of insulin absorption, including direct insulin release from the delivery system and endocytosis by M cells and macrophages. In the streptozotocin (STZ)-induced type 1 diabetic mouse model, CV@INS@ALG showed a more effective and long-lasting hypoglycemic effect than direct insulin injection and did not cause any damage to the intestinal tract. Additionally, the long-term oral administration of the carrier CV@ALG effectively ameliorated gut microbiota disorder, and significantly increased the abundance of probiotic A kkermansia in db / db type 2 diabetic mice, thereby enhancing the insulin sensitivity of mice. Microalgal insulin delivery systems could be degraded and metabolized in the intestinal tract after oral administration, showing good biodegradability and biosafety. This insulin delivery strategy based on microalgal biomaterials provides a natural, efficient, and multifunctional solution for oral insulin delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Haining 314400, China

Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China

Wenzhou Medical College, Wenzhou 325035, China

Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China

Funding

Zhejiang University · Primary Research and Development Plan of Zhejiang Province · National Key Research and Development Program of China · National Natural Science Foundation of China · Fundamental Research Funds for the Zhejiang Provincial Universities

References (46)

Show source-provided references
1. 10.1038/485S1a10.1038/485S1a ↗
2. 10.1503/cmaj.18076210.1503/cmaj.180762 ↗
3. 10.1038/nrendo.2016.5310.1038/nrendo.2016.53 ↗
4. 10.1016/S0140-6736(13)62715-410.1016/S0140-6736(13)62715-4 ↗
5. 10.1136/bmj.d29410.1136/bmj.d294 ↗
6. 10.1210/er.2015-113710.1210/er.2015-1137 ↗
7. 10.1038/nrendo.2017.15110.1038/nrendo.2017.151 ↗
8. 10.1038/s41574-020-0381-510.1038/s41574-020-0381-5 ↗
9. 10.1038/s41574-021-00507-z10.1038/s41574-021-00507-z ↗
10. 10.1111/joim.1285910.1111/joim.12859 ↗
11. 10.1007/s00592-019-01326-510.1007/s00592-019-01326-5 ↗
12. 10.2174/138920101966618091811292210.2174/1389201019666180918112922 ↗
13. 10.3109/1071754100376288810.3109/10717541003762888 ↗
14. 10.3109/10717544.2014.91676910.3109/10717544.2014.916769 ↗
15. 10.1038/s41573-019-0053-010.1038/s41573-019-0053-0 ↗
16. 10.1002/anie.20200887910.1002/anie.202008879 ↗
17. 10.1021/bc100093v10.1021/bc100093v ↗
18. 10.1016/S0927-7765(99)00157-510.1016/S0927-7765(99)00157-5 ↗
19. 10.1016/j.jconrel.2016.04.00210.1016/j.jconrel.2016.04.002 ↗
20. 10.1016/j.jconrel.2016.12.01810.1016/j.jconrel.2016.12.018 ↗
21. 10.3390/pharmaceutics1203025910.3390/pharmaceutics12030259 ↗
22. 10.3390/pharmaceutics1205046210.3390/pharmaceutics12050462 ↗
23. 10.1021/bc050344k10.1021/bc050344k ↗
24. 10.1021/acsmacrolett.7b0003510.1021/acsmacrolett.7b00035 ↗
25. 10.1016/j.bioactmat.2021.08.00710.1016/j.bioactmat.2021.08.007 ↗
26. 10.1002/adhm.20180112310.1002/adhm.201801123 ↗
27. 10.1021/acs.biomac.7b0132210.1021/acs.biomac.7b01322 ↗
28. 10.1021/acsami.1c0058010.1021/acsami.1c00580 ↗
29. 10.1080/10717544.2018.155143910.1080/10717544.2018.1551439 ↗
30. 10.1016/j.msec.2019.10975310.1016/j.msec.2019.109753 ↗
31. 10.2174/138161282266615111214522610.2174/1381612822666151112145226 ↗
32. 10.1016/j.psyneuen.2015.12.00210.1016/j.psyneuen.2015.12.002 ↗
33. 10.1016/j.fsi.2019.12.00910.1016/j.fsi.2019.12.009 ↗
34. 10.4162/nrp.2009.3.1.2310.4162/nrp.2009.3.1.23 ↗
35. 10.1021/acs.jafc.1c0229410.1021/acs.jafc.1c02294 ↗
36. 10.3390/nu1308281210.3390/nu13082812 ↗
37. 10.1021/bm401890x10.1021/bm401890x ↗
38. 10.1021/acsabm.9b0081310.1021/acsabm.9b00813 ↗
39. 10.1016/j.jconrel.2006.12.02310.1016/j.jconrel.2006.12.023 ↗
40. 10.1002/jps.2187410.1002/jps.21874 ↗
41. 10.1126/sciadv.aba599610.1126/sciadv.aba5996 ↗
42. 10.1002/smll.20200081910.1002/smll.202000819 ↗
43. 10.1002/adfm.20191039510.1002/adfm.201910395 ↗
44. 10.1208/s12249-021-02041-710.1208/s12249-021-02041-7 ↗
45. 10.1038/s41564-021-00880-510.1038/s41564-021-00880-5 ↗
46. 10.1186/s40168-021-01126-610.1186/s40168-021-01126-6 ↗